Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-21 20:28:08 UTC |
---|
Update Date | 2014-12-24 20:25:54 UTC |
---|
Accession Number | T3D2954 |
---|
Identification |
---|
Common Name | Frovatriptan |
---|
Class | Small Molecule |
---|
Description | Frovatriptan (Frova™) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1] Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.
Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.
Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006[2] and which is currently pending.[3] The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova™ will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM). |
---|
Compound Type | - Amide
- Amine
- Anti-Inflammatory Agent
- Anti-Migraine Agent
- Drug
- Ester
- Metabolite
- Organic Compound
- Serotonin Agonist
- Serotonin Receptor Agonist
- Synthetic Compound
- Vasoconstrictor Agent
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | Allergo filmtabletten | Frova | Frovatriptan succinate | Frovelan | Miguard |
|
---|
Chemical Formula | C14H17N3O |
---|
Average Molecular Mass | 243.304 g/mol |
---|
Monoisotopic Mass | 243.137 g/mol |
---|
CAS Registry Number | 158747-02-5 |
---|
IUPAC Name | (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide |
---|
Traditional Name | frovatriptan |
---|
SMILES | [H][C@]1(CCC2=C(C1)C1=C(N2)C=CC(=C1)C(O)=N)NC |
---|
InChI Identifier | InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 |
---|
InChI Key | InChIKey=XPSQPHWEGNHMSK-SECBINFHSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as carbazoles. Carbazoles are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Indoles and derivatives |
---|
Sub Class | Carbazoles |
---|
Direct Parent | Carbazoles |
---|
Alternative Parents | |
---|
Substituents | - Carbazole
- Indolecarboxamide derivative
- Indolecarboxylic acid derivative
- 3-alkylindole
- Indole
- Aralkylamine
- Benzenoid
- Heteroaromatic compound
- Pyrrole
- Amino acid or derivatives
- Carboxamide group
- Primary carboxylic acid amide
- Carboxylic acid derivative
- Secondary aliphatic amine
- Azacycle
- Secondary amine
- Hydrocarbon derivative
- Organic oxide
- Organic nitrogen compound
- Amine
- Organopnictogen compound
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | Not Available | Boiling Point | Not Available | Solubility | Soluble | LogP | 0.9 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-004i-3690000000-20d2133e95fbc6b1f414 | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0006-0190000000-fc527e672048d9bf866c | 2016-08-02 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-004i-0490000000-09182e67659519af87e7 | 2016-08-02 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0l1i-0910000000-81f4aa818323e96b5464 | 2016-08-02 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-0090000000-bd79ad698f8bd9fbb84b | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-2490000000-4632cbf11a6dc353d2cf | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0006-9200000000-948170ac23122892a5ad | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0006-0090000000-168fda82142bf345541b | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-002f-0090000000-3dac4efa84856ab16486 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-000i-0910000000-bdfabb283d321aa1d9e3 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-0090000000-932ee60351365d51e611 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-1190000000-c3fd5753f8f9a8a098eb | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0006-4910000000-8fac1192455fd2253b72 | 2021-10-11 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Frovatriptan is rapidly absorbed from the duodenum, but has low oral bioavailability. |
---|
Mechanism of Toxicity | Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism. |
---|
Metabolism | In vitro, cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan to several metabolites including hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, and several other minor metabolites. Desmethyl frovatriptan has lower affinity for 5-HT1B/1D receptors compared to the parent compound. The N-acetyl desmethyl metabolite has no significant affinity for 5-HT receptors. The activity of the other metabolites is unknown.
Route of Elimination: Radiolabeled compounds excreted in urine were unchanged frovatriptan, hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, together with several other minor metabolites. Less than 10% of frovatriptan was excreted in urine after an oral dose.
Half Life: 26 hours |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | For the acute treatment of migraine attacks with or without aura in adults. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | There is no direct experience of any patient taking an overdose of Frovatriptan. The maximum single dose of frovatriptan given to male and female patients with migraine was 40 mg (16 times the clinical dose) and the maximum single dose given to healthy male subjects was 100 mg (40 times the clinical dose) without significant adverse events. |
---|
Treatment | As with other 5-HT1 receptor agonists, there is no specific antidote for frovatriptan. The elimination half-life of frovatriptan is 26 hours, therefore if overdose occurs, the patient should be monitored closely for at least 48 hours and be given any necessary symptomatic treatment. (8) |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00998 |
---|
HMDB ID | HMDB15133 |
---|
PubChem Compound ID | 77992 |
---|
ChEMBL ID | CHEMBL1279 |
---|
ChemSpider ID | 70378 |
---|
KEGG ID | Not Available |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 350328 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Frovatriptan |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Frovatriptan |
---|
References |
---|
Synthesis Reference | Samir Naik, Anthony Crasto, Narendra Joshi, Sachin Srivastava, “Amorphous frovatriptan succinate and process for the preparation thereof.” U.S. Patent US20070299123, issued December 27, 2007. |
---|
MSDS | Not Available |
---|
General References | - Markus F, Mikko K: Frovatriptan review. Expert Opin Pharmacother. 2007 Dec;8(17):3029-33. [18001261 ]
- Easthope SE, Goa KL: Frovatriptan. CNS Drugs. 2001;15(12):969-76; discussion 977-8. [11735616 ]
- Balbisi EA: Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Sep;2(3):303-8. [18360605 ]
- Balbisi EA: Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract. 2004 Jul;58(7):695-705. [15311727 ]
- Elkind AH, Wade A, Ishkanian G: Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol. 2004 Oct;44(10):1158-65. [15342617 ]
- Jhee SS, Shiovitz T, Crawford AW, Cutler NR: Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. [11327198 ]
- Drugs.com [Link]
- RxList: The Internet Drug Index (2009). [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|